Contact

Our portfolio

Parkinnova Therapeutics

Parkinnova Therapeutics, focuses on developing novel treatments for midbrain dopamine disorders like Parkinson’s disease. The company targets the PDE11a pathway to upregulate dopamine production. Parkinnova aims to bring innovative therapies to clinical trials, addressing significant unmet needs in neurodegenerative diseases. The company is committed to advancing neuroscience through cutting-edge research.

  • Institute: University of Amsterdam
Industry: Neuroscience, Therapeutics
  • Founding year: 2024
Visit website

Want to get in contact about Parkinnova Therapeutics?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
ikHerstel
Speeding up post-surgical rehabilitation with a personalized e-health recovery platform.

OpticsFoundry

OpticsFoundry
Revolutionizing optical circuit manufacturing by offering robotically assembled and modular optical circuit boards that are easy to design, order, and deploy.
AIBiomics
Developing rapid human gut microbiota analysis.
Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
ikHerstel
Speeding up post-surgical rehabilitation with a personalized e-health recovery platform.

OpticsFoundry

OpticsFoundry
Revolutionizing optical circuit manufacturing by offering robotically assembled and modular optical circuit boards that are easy to design, order, and deploy.
AIBiomics
Developing rapid human gut microbiota analysis.
Explore full AAV portfolio
Contact